E-LIB Suche - Ergebnisse für: Beckermann, Kathryn E

1

A phase 1b open-label study to evaluate the safety, tolerab..:

Beckermann, Kathryn E. ; Patnaik, Amita ; Winer, Ira...
Investigational New Drugs. 42 (2024) 2 - p. 179-184 , 2024

2

HIF-2α expression and metabolic signaling require ACSS2 in ..:

Bacigalupa, Zachary A. ; Arner, Emily N. ; Vlach, Logan M....
Journal of Clinical Investigation. 134 (2024) 12 - p. , 2024

Link: https://doi.org/10.1172/..

3

A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Inte..:

Brugarolas, James ; Obara, Gregory ; Beckermann, Kathryn E....
Clinical Cancer Research. 30 (2024) 11 - p. 2402-2411 , 2024

Link: https://doi.org/10.1158/..

4

A Phase 1/2 Study to Evaluate the Safety and Activity of Ni..:

Beckermann, Kathryn E. ; Bestvina, Christine M. ; El Osta, Badi...
JTO Clinical and Research Reports. 5 (2024) 2 - p. 100619 , 2024

Link: https://doi.org/10.1016/..

5

Author Correction: Obesity induces PD-1 on macrophages to s..:

Bader, Jackie E. ; Wolf, Melissa M. ; Lupica-Tondo, Gian Luca...
Nature. 631 (2024) 8022 - p. E16-E16 , 2024

Link: https://doi.org/10.1038/..

6

Metabolite profiling of human renal cell carcinoma reveals ..:

Reinfeld, Bradley I ; Ali, Ahmed ; Abbott, Keene L...
eLife. 13 (2024) - p. , 2024

Link: https://doi.org/10.7554/..

7

Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion..:

Else, Tobias ; Jonasch, Eric ; Iliopoulos, Othon...
Clinical Cancer Research. 30 (2024) 9 - p. 1750-1757 , 2024

Link: https://doi.org/10.1158/..

8

Obesity induces PD-1 on macrophages to suppress anti-tumour..:

Bader, Jackie E. ; Wolf, Melissa M. ; Lupica-Tondo, Gian Luca...
Nature. 630 (2024) 8018 - p. 968-975 , 2024

Link: https://doi.org/10.1038/..

9

Long-Term Survival in Patients With Relapsed/Refractory Adv..:

Beckermann, Kathryn E ; Asnis-Alibozek, Aviva G ; Atkins, Michael B...
The Oncologist. 29 (2024) 3 - p. 254-262 , 2024

Link: https://doi.org/10.1093/..

10

Metabolite profiling of human renal cell carcinoma reveals ..:

Reinfeld, Bradley I ; Ali, Ahmed ; Abbott, Keene L...
eLife. 13 (2024) - p. , 2024

Link: https://doi.org/10.7554/..

11

VHL loss reprograms the immune landscape to promote an infl..:

Wolf, Melissa M. ; Madden, Matthew Z. ; Arner, Emily N....
Journal of Clinical Investigation. 134 (2024) 8 - p. , 2024

Link: https://doi.org/10.1172/..

12

CTNI-71. BELZUTIFAN FOR VON HIPPEL-LINDAU DISEASE-RELATED C..:

Iliopoulos, Othon ; Iversen, Ane B ; Narayan, Vivek...
Neuro-Oncology. 25 (2023) Supplement_5 - p. v93-v93 , 2023

Link: https://doi.org/10.1093/..

13

A triple dose of optimism: an initial foray into triplet th..:

Beckermann, Kathryn E. ; Rini, Brian I.
Nature Reviews Clinical Oncology. 20 (2023) 9 - p. 581-582 , 2023

Link: https://doi.org/10.1038/..

14

SYST-18 BELZUTIFAN TREATMENT FOR PATIENTS WITH VON HIPPEL-L..:

Narayan, Vivek ; Iliopoulos, Othon ; Iversen, Ane B...
Neuro-Oncology Advances. 5 (2023) Supplement_3 - p. iii31-iii31 , 2023

Link: https://doi.org/10.1093/..

15

Sequencing checkpoint inhibitor therapy in renal cell carci..:

Beckermann, Kathryn E ; Rini, Brian I
The Lancet. 402 (2023) 10397 - p. 160-161 , 2023

Link: https://doi.org/10.1016/..